Literature DB >> 32215649

Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis.

Mariëlle Kloosterman1, Jonas Oldgren2, David Conen3, Jorge A Wong3, Stuart J Connolly3, Alvaro Avezum4, Salim Yusuf3, Michael D Ezekowitz5, Lars Wallentin2, Marie Ntep-Gweth6, Philip Joseph3, Tyler W Barrett7, Supachai Tanosmsup8, William F McIntyre3, Shun Fu Lee3, Ratika Parkash9, Guy Amit3, Alex Grinvalds3, Isabelle C Van Gelder1, Jeff S Healey3.   

Abstract

AIMS: Data on patient characteristics, prevalence, and outcomes of atrial fibrillation (AF) patients without traditional risk factors, often labelled 'lone AF', are sparse. METHODS AND
RESULTS: The RE-LY AF registry included 15 400 individuals who presented to emergency departments with AF in 47 countries. This analysis focused on patients without traditional risk factors, including age ≥60 years, hypertension, coronary artery disease, heart failure, left ventricular hypertrophy, congenital heart disease, pulmonary disease, valve heart disease, hyperthyroidism, and prior cardiac surgery. Patients without traditional risk factors were compared with age- and region-matched controls with traditional risk factors (1:3 fashion). In 796 (5%) patients, no traditional risk factors were present. However, 98% (779/796) had less-established or borderline risk factors, including borderline hypertension (130-140/80-90 mmHg; 47%), chronic kidney disease (eGFR < 60 mL/min; 57%), obesity (body mass index > 30; 19%), diabetes (5%), excessive alcohol intake (>14 units/week; 4%), and smoking (25%). Compared with patients with traditional risk factors (n = 2388), patients without traditional risk factors were more often men (74% vs. 59%, P < 0.001) had paroxysmal AF (55% vs. 37%, P < 0.001) and less AF persistence after 1 year (21% vs. 49%, P < 0.001). Furthermore, 1-year stroke occurrence rate (0.6% vs. 2.0%, P = 0.013) and heart failure hospitalizations (0.9% vs. 12.5%, P < 0.001) were lower. However, risk of AF-related re-hospitalization was similar (18% vs. 21%, P = 0.09).
CONCLUSION: Almost all patients without traditionally defined AF risk factors have less-established or borderline risk factors. These patients have a favourable 1-year prognosis, but risk of AF-related re-hospitalization remains high. Greater emphasis should be placed on recognition and management of less-established or borderline risk factors. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation hospitalization; Borderline risk factors; Less-established risk factors; Lone atrial fibrillation; Registry; Substrate

Year:  2020        PMID: 32215649      PMCID: PMC7273333          DOI: 10.1093/europace/euz360

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  20 in total

1.  Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.

Authors:  Michiel Rienstra; Anne H Hobbelt; Marco Alings; Jan G P Tijssen; Marcelle D Smit; Johan Brügemann; Bastiaan Geelhoed; Robert G Tieleman; Hans L Hillege; Raymond Tukkie; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C Van Gelder
Journal:  Eur Heart J       Date:  2018-08-21       Impact factor: 29.983

2.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

3.  Atrial fibrillation progression and outcome in patients with young-onset atrial fibrillation.

Authors:  Ruben R De With; Ernaldo G Marcos; Isabelle C Van Gelder; Michiel Rienstra
Journal:  Europace       Date:  2018-11-01       Impact factor: 5.214

4.  Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study.

Authors:  Michiel Rienstra; Isabelle C Van Gelder; Vincent E Hagens; Nic J G M Veeger; Dirk J Van Veldhuisen; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2005-11-07       Impact factor: 29.983

5.  Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I.

Authors:  X Jouven; M Desnos; C Guerot; P Ducimetiere
Journal:  Eur Heart J       Date:  1999-06       Impact factor: 29.983

6.  The occurrence of cardiovascular disease during 5-year follow-up in patients with idiopathic atrial fibrillation.

Authors:  B Weijs; C B de Vos; R G Tieleman; F E C M Peeters; I Limantoro; A A Kroon; E C Cheriex; R Pisters; H J G M Crijns
Journal:  Europace       Date:  2012-07-10       Impact factor: 5.214

7.  The natural history of lone atrial fibrillation. A population-based study over three decades.

Authors:  S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

8.  Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry.

Authors:  Jonas Oldgren; Jeff S Healey; Michael Ezekowitz; Patrick Commerford; Alvaro Avezum; Prem Pais; Jun Zhu; Petr Jansky; Alben Sigamani; Carlos A Morillo; Lisheng Liu; Albertino Damasceno; Alex Grinvalds; Juliet Nakamya; Paul A Reilly; Katalin Keltai; Isabelle C Van Gelder; Afzal Hussein Yusufali; Eiichi Watanabe; Lars Wallentin; Stuart J Connolly; Salim Yusuf
Journal:  Circulation       Date:  2014-01-24       Impact factor: 29.690

Review 9.  Lone atrial fibrillation: does it exist?

Authors:  D George Wyse; Isabelle C Van Gelder; Patrick T Ellinor; Alan S Go; Jonathan M Kalman; Sanjiv M Narayan; Stanley Nattel; Ulrich Schotten; Michiel Rienstra
Journal:  J Am Coll Cardiol       Date:  2014-02-12       Impact factor: 24.094

10.  Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study.

Authors:  Arshad Jahangir; Victor Lee; Paul A Friedman; Jane M Trusty; David O Hodge; Stephen L Kopecky; Douglas L Packer; Stephen C Hammill; Win-Kuang Shen; Bernard J Gersh
Journal:  Circulation       Date:  2007-06-04       Impact factor: 29.690

View more
  6 in total

1.  Prediction of risk factors for recurrence of atrial fibrillation in patients with arterial hypertension.

Authors:  Cam Dinh Truong; Binh Thanh Nguyen; Thang Van Cong Tran
Journal:  Int J Cardiovasc Imaging       Date:  2021-07-03       Impact factor: 2.357

2.  Atrial fibrillation: villain or bystander in vascular brain injury.

Authors:  Ben Freedman; Hooman Kamel; Isabelle C Van Gelder; Renate B Schnabel
Journal:  Eur Heart J Suppl       Date:  2020-12-06       Impact factor: 1.803

3.  Feasibility of weight loss in obese atrial fibrillation patients attending a specialist arrhythmia clinic and its impact on ablation outcomes.

Authors:  Wern Yew Ding; Nikola Kozhuharov; Shui Hao Chin; Matthew Shaw; Richard Snowdon; Gregory Y H Lip; Dhiraj Gupta
Journal:  J Arrhythm       Date:  2020-09-13

4.  Comparison of risk profiles for new-onset atrial fibrillation between patients aged <60 and ≥60 years.

Authors:  In-Soo Kim; Yeon-Jik Choi; Eui-Young Choi; Pil-Ki Min; Young Won Yoon; Byoung Kwon Lee; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon; Jong-Youn Kim
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.752

5.  Ischemic Stroke in Non-Gender-Related CHA2DS2-VA Score 0~1 Is Associated With H2FPEF Score Among the Patients With Atrial Fibrillation.

Authors:  Min Kim; Hee Tae Yu; Tae-Hoon Kim; Dae-In Lee; Jae-Sun Uhm; Young Dae Kim; Hyo Suk Nam; Boyoung Joung; Moon-Hyoung Lee; Ji Hoe Heo; Hui-Nam Pak
Journal:  Front Cardiovasc Med       Date:  2022-02-08

6.  Prognosis of Atrial Fibrillation with or without Comorbidities: Analysis of Younger Adults from a Nationwide Database.

Authors:  Valentin Mertz; Yves Cottin; Sid Ahmed Bentounes; Julie Pastier-Debeaumarché; Romain Didier; Julien Herbert; Marianne Zeller; Gregory Y H Lip; Laurent Fauchier
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.